AbbVie replaces retiring VP of Western Europe and Canada
January 15, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Esteban Plata, Pascale Richetta
AbbVie has appointed Esteban Plata as vice president of Western Europe and Canada.He replaces Pascale Richetta who is retiring from …
Patient involvement ‘would improve medicines R&D’
January 15, 2016Medical Communications, Research and Development EUPATI, Patient and Public Involvement, R&D
A new study has revealed a belief among pharma industry executives that greater involvement of patients and the public could …
Wave Healthcare Communications – Four predictions for med ed in 2016
January 14, 2016Medical Communications medical education
These are some of the trends Wave foresees in the forthcoming year: Integration We predict there will be a greater …
FDA says no to BioMarin’s Duchenne Muscular Dystrophy drug
January 14, 2016Medical Communications, Sales and Marketing BioMarin, Duchenne Muscular Dystrophy, FDA, Kyndrisa, drisapersen
The FDA has rejected BioMarin’s Duchenne Muscular Dystrophy (DMD) drug Kyndrisa, saying there was not enough evidence that the drug …
Pfizer may sell off Hospira unit for $2 billion
January 14, 2016Manufacturing and Production, Medical Communications, Sales and Marketing Hospira, Pfizer, injectables, pumps
Pfizer is reportedly considering selling Hospira’s infusion pump business for around $2 billion, having acquired the injectable drugs and infusion …
US Federal Trade Commission clamps down on pharma ‘pay to delay’ deals
January 14, 2016Manufacturing and Production, Sales and Marketing Pay to delay, US Supreme Court, antitrust laws, federal trade commission, generic competition, generics, patents, pay for delay
Pharma companies were able to negotiate far fewer so-called ‘pay to delay’ cases as a strategy to stave off generic …
Takeda in myeloma research drive
January 14, 2016Medical Communications, Research and Development Ninlaro, Phase II, Takeda, Takeda oncology, eric low, ixazomib, multiple myeloma, myeloma
Takeda is funding the research charity Myeloma UK to run a Phase II study of its multiple myeloma treatment Ninlaro, …
A brighter future for the Cancer Drugs Fund?
January 14, 2016Sales and Marketing Cancer Drugs Fund, NHS England, NICE, Prostate Cancer UK
In November 2015, NICE and NHS England announced proposed changes to the operation of the Cancer Drugs Fund. This is …
Illumina forms spin-off to develop cancer detection test
January 14, 2016Research and Development Cancer, Illumina, cancer detection, gene sequencing, liquid biospy, oncology
Global gene sequencing company Illumina has won over $100 million in investment from high-profile investors, to create a company “to …
Baxalta’s Enbrel biosimilar measures up in late-stage study
January 13, 2016Research and Development Amgen, Baxalta, Enbrel, Pfizer, biosimilar, etanercept, rheumatoid arthritis
Having emerged from its mega-merger deal with Shire, Baxalta is back on its drug development day job – and has …
BioLineRx to test lead candidate with MSD’s Keytruda in pancreatic cancer
January 13, 2016Research and Development MSD, immunotherapy, keytruda, pembrolizumab
Israeli biopharma company BioLineRx has announced a collaboration with MSD on a Phase II study investigating its lead oncology candidate, …
Big pharma joins President Obama’s cancer ‘moonshot’
January 13, 2016Research and Development Amgen, Cancer, Celgene, National Immunotherapy Coalition, President Barack Obama, US, moonshot
Celgene and Amgen are among the large biopharma companies that have agreed to join the National Immunotherapy Coalition (NIC), a …
Cell and Gene Therapy World: PCI Pharma Services expert to present on cold chain challenges
January 13, 2016Medical Communications
Leading pharmaceutical provider PCI Pharma Services will bring its expertise to the stage at Cell and Gene Therapy World (January …
Senate panel approves Dr Robert Califf as FDA commissioner
January 13, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Dr Robert Califf, FDA, FDA commissioner, Senate
A senate panel has approved president Obama’s nominee Dr Robert Califf to lead the FDA by a clear majority, although …
Takeda and enGene partner to develop gastro drugs
January 13, 2016Research and Development Takeda
Takeda is teaming up with Canadian biotech enGene to develop novel therapies for specialty gastrointestinal (GI) diseases, using enGene’s ‘gene …
MedImmune and UCSF team up to research RAI treatments
January 13, 2016Research and Development MedImmune, Precision Medicine, University of California San Francisco, autoimmunity
AstraZeneca’s biologics R&D arm MedImmune and the University of California, San Francisco (UCSF) have announced a new research collaboration focused …
MSD to acquire Scottish firm IOmet Pharma
January 12, 2016Research and Development, Sales and Marketing IOMet Pharma, MSD, Merck, Scotland, acquisitions, immuno-oncology, mergers, oncology
US pharma company MSD is to buy Edinburgh based IOMet Pharma to expand its existing R&D programme, exploring the development …
Eisai submits new cancer combo to EMA for approval
January 12, 2016Sales and Marketing Afinitor, EMA, Eisai, Lenvima, MAA, Novartis, everolimus, lenvatinib
Eisai has submitted a new Marketing Authorisation Application to the EMA for the combination of Lenvima and Novartis’ Afinitor for …
SMC approves first ever treatment for genetic kidney disease
January 12, 2016Sales and Marketing Otsuka, SMC, Scottish Medicines Consortium, jinarc, kidney disease, tolvaptan
The Scottish Medicines Consortium (SMC) has approved Otsuka’s Jinarc for the treatment of the genetic kidney disease autosomal dominant polycystic …
Former Novartis site to be developed into science park
January 12, 2016Manufacturing and Production Employment, Jobs, Life science, Novartis, West Sussex, science park
Work has begun to transform a 20-acre site that formerly housed Novartis, in West Sussex, into a world renowned centre …
Latest content
Brenntag and dsm-firmenich expand biopharma vitamin partnership
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
